Table 1.
Baseline characteristics and procedure detail before and after propensity score matching.
| Before matching |
After matching |
|||||
|---|---|---|---|---|---|---|
| BA group | NT group | p-value | BA group | NT group | p-value | |
| Patient characteristics, n | 729 | 2029 | 572 | 572 | ||
| Age (years; mean ± SD) | 72 ± 9 | 73 ± 9 | 0.9341 | 72 ± 9 | 73 ± 10 | 0.7712 |
| Female, n (%) | 240 (33) | 596 (29) | 0.0738 | 163 (28) | 179 (31) | 0.3015 |
| Ambulatory, n (%) | 596 (82) | 1746 (86) | 0.0068 | 475 (83) | 487 (85) | 0.3320 |
| Hypertension, n (%) | 582 (80) | 1724 (85) | 0.0017 | 472 (83) | 473 (83) | 0.9378 |
| Dyslipidemia, n (%) | 340 (47) | 1006 (50) | 0.1827 | 287 (50) | 288 (50) | 0.9528 |
| Diabetes mellitus, n (%) | 436 (60) | 1215 (60) | 0.9968 | 349 (61) | 343 (60) | 0.7167 |
| Regular dialysis, n (%) | 237 (33) | 469 (23) | <0.0001 | 169 (30) | 159 (28) | 0.5133 |
| Current smoking, n (%) | 157 (22) | 523 (26) | 0.0238 | 144 (25) | 151 (26) | 0.6361 |
| Cilostazol, n (%) | 255 (35) | 1028 (51) | <0.0001 | 218 (38) | 225 (39) | 0.6709 |
| Statin, n (%) | 256 (35) | 768 (38) | 0.1981 | 216 (38) | 208 (36) | 0.6243 |
| ACEI/ARB, n (%) | 343 (47) | 1071 (53) | 0.0087 | 293 (51) | 286 (50) | 0.6789 |
| CLI, n (%) | 249 (34) | 630 (31) | 0.0971 | 174 (30) | 176 (31) | 0.8979 |
| Lesion characteristics, n | 950 | 2520 | 572 | 572 | ||
| TASC II C/D, n (%) | 113 (12) | 1255 (50) | <0.0001 | 93 (16) | 104 (18) | 0.3890 |
| LL (mm; mean ± SD) | 64 ± 60 | 141 ± 88 | <0.0001 | 78 ± 68 | 80 ± 59 | 0.5873 |
| Reference diameter (mm; mean ± SD) | 4.9 ± 1.1 | 5.3 ± 0.9 | <0.0001 | 5.2 ± 1.1 | 5.1 ± 0.8 | 0.2749 |
| Calcification, n (%) | 609 (64) | 1439 (57) | 0.0002 | 326 (57) | 346 (60) | 0.2297 |
| CTO, n (%) | 251 (26) | 1322 (52) | <0.0001 | 192 (34) | 201 (35) | 0.5753 |
| Poor run-off, n (%) | 382 (40) | 1058 (42) | 0.0179 | 242 (42) | 237 (41) | 0.7644 |
| Procedure detail, n | 950 | 2520 | 572 | 572 | ||
| IVUS use, n (%) | 115 (12) | 621 (25) | <0.0001 | 96 (17) | 96 (17) | 1.0000 |
SD: standard deviation; BA: balloon angioplasty; NT: nitinol stenting; ACEI: angiotensin-converting enzyme inhibitor; ARB: angiotensin II receptor blocker; CLI: critical limb ischemia; TASC: Trans-Atlantic Inter-Society Consensus; LL: lesion length; CTO: chronic total occlusion; IVUS: intra-vascular ultra-sonography.